Denali reports a PhII ALS fail as RIPK1 deal with Sanofi hits another bump

Sanofi and De­nali Ther­a­peu­tics’ part­ner­ship ran in­to yet an­oth­er stum­bling block af­ter their ALS pro­gram failed a Phase II study.

DNL788 did not achieve the pri­ma­ry end­point in the tri­al as it failed to show a dif­fer­ence in the re­vised ALS Func­tion­al Rat­ing Scale (ALS­FRS-R), ac­cord­ing to an SEC fil­ing on Fri­day. Ex­act da­ta fig­ures were not dis­closed, but De­nali not­ed that Sanofi in­tends to share the full re­sults at a fu­ture med­ical con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.